Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.
暂无分享,去创建一个
T. Mavrakanas | M. Lipman | C. Samer | S. Nessim | G. Frisch
[1] D. Brancaccio,et al. Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study , 2016, American Journal of Nephrology.
[2] A. Parkhomenko,et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. , 2016, JAMA cardiology.
[3] J. Piccini,et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. , 2016, Journal of the American College of Cardiology.
[4] C. Frost,et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis , 2016, Journal of clinical pharmacology.
[5] A. Shenker,et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban , 2016, Journal of clinical pharmacology.
[6] D. Brancaccio,et al. Atrial Fibrillation in Dialysis Patients: Time to Abandon Warfarin? , 2016, The International journal of artificial organs.
[7] S. Connolly,et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. , 2015, The New England journal of medicine.
[8] Jenny I. Shen,et al. Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] R. Malmström,et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. , 2015, Thrombosis research.
[10] Alan B Leichtman,et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] D. De Bacquer,et al. Dose-finding study of rivaroxaban in hemodialysis patients. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] P. Fontana,et al. Direct oral anticoagulants: efficacy and safety in patient subgroups. , 2015, Swiss medical weekly.
[13] M. Battistella,et al. Evaluating time in therapeutic range for hemodialysis patients taking warfarin. , 2015, Clinical nephrology.
[14] C. Frost,et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. , 2014, International journal of clinical pharmacology and therapeutics.
[15] J. Tu,et al. Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis , 2014, Circulation.
[16] S. Laporte,et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays , 2013, Thrombosis and Haemostasis.
[17] A. Shenker,et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. , 2013, British journal of clinical pharmacology.
[18] J. Dogné,et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide , 2013, Thrombosis and Haemostasis.
[19] G. Raskob,et al. Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.
[20] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[21] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[22] L. Køber,et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.
[23] C. Rowley. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[24] W. Winkelmayer,et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[25] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[26] W. Winkelmayer,et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. , 2011, Journal of the American Society of Nephrology : JASN.
[27] T. Leil,et al. Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose , 2010, Clinical pharmacology and therapeutics.
[28] P. Kerr,et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. , 2010, Kidney international.
[29] R. Thadhani,et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. , 2009, Journal of the American Society of Nephrology : JASN.
[30] W. Humphreys,et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans , 2009, Drug Metabolism and Disposition.
[31] J. Danziger. Vitamin K-dependent proteins, warfarin, and vascular calcification. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[32] M. Aguilar,et al. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. , 2007, Annals of internal medicine.
[33] Angela Smallwood,et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2007, Journal of medicinal chemistry.
[34] T. Palfai,et al. Brief Intervention for Medical Inpatients with Unhealthy Alcohol Use , 2007, Annals of Internal Medicine.
[35] B. Kestenbaum,et al. Elevated risk of stroke among patients with end-stage renal disease. , 2003, Kidney international.